BRIEF-Gilead Says Submitted Request To FDA To Waive All Benefits That Accompany Orphan Drug Designation

Gilead Sciences Inc:

* GILEAD SCIENCES SAYS SUBMITTED REQUEST TO U.S. FDA TO RESCIND ORPHAN DRUG DESIGNATION GRANTED FOR INVESTIGATIONAL ANTIVIRAL FOR TREATMENT OF COVID19

* GILEAD SCIENCES SAYS SUBMITTED REQUEST TO U.S. FDA TO WAIVE ALL BENEFITS THAT ACCOMPANY THE ORPHAN DRUG DESIGNATION Source text : [ID:https://bit.ly/3dtO0lu] Further company coverage: